

**AAKAAR MEDICAL TECHNOLOGIES LIMITED**

(Formerly known as AAKAAR MEDICAL TECHNOLOGIES PRIVATE LIMITED)

Registered Address: A-801, Heritage Plaza, Teli Gali, Cross Road, Andheri (E), Mumbai 400069

CIN : L74900MH2013PLC244717

Statement of Unaudited Standalone Financial Results for the half year ended September 30, 2026

(Amount in Lacs except EPS)

Particulars	For the half year ended		For the year ended
	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	March 31, 2026 (Audited)
I Revenue from operations	4,372.34	2532.49	6,696.41
II Other income	26.80	29.71	80.44
III Total income (I + II)	4,399.13	2,562.21	6,776.85
IV Expenses:			
Cost of material consumed	110.30	202.82	440.98
Purchases of Stock-in-Trade	2,633.85	1,397.35	2,899.13
Changes in inventories of Stock-in-Trade and finished goods	(619.11)	(455.71)	(519.61)
Employee benefit expense	807.02	726.40	1,401.08
Finance costs	80.85	104.07	179.61
Depreciation and amortisation expenses	6.81	4.91	12.83
Other expenses	897.46	684.70	1,443.64
Total expenses	3,917.17	2,664.54	5,857.67
V Profit before tax (III-IV)	481.96	(102.33)	919.18
VI Prior period items	-	-	-
VII Tax expense:			
Current tax expense for the year	131.52	(18.54)	244.08
Short/ (excess) provision	3.22	-	18.71
Deferred tax expenses	(6.86)	(5.38)	(7.38)
	127.88	(23.93)	255.42
VIII Profit/ (Loss) for the period (V-VI-VII)	354.09	(78.41)	663.76
IX Earnings per equity share (EPS):			
Basic	2.50	(0.63)	4.99
Diluted	2.50	(0.63)	4.99

See accompanying Notes to Financial Results

Place: Mumbai
Date: October 30, 2026



For and on behalf of
Aakaar Medical Technologies Limited

Dilip Meswani
Managing Director
DIN 06540985

**AAKAAR MEDICAL TECHNOLOGIES LIMITED**

(Formerly known as AAKAAR MEDICAL TECHNOLOGIES PRIVATE LIMITED)

Registered Address: A-801, Heritage Plaza, Teli Gali, Cross Road, Andheri (E), Mumbai 400069

CIN : L74900MH2013PLC244717

Statements of Assets and Liabilities as at September 30, 2026

(Amount in Lacs)

Particulars	As at	
	September 30, 2026 (Unaudited)	March 31, 2026 (Audited)
EQUITY AND LIABILITIES		
1 Equity		
Shareholders' funds		
(a) Share capital	1,417.28	1,417.28
(b) Reserves and surplus	4,391.77	4,037.78
	5,809.05	5,455.06
2 Liabilities		
Non-current liabilities		
(a) Long-term provisions	115.16	98.29
(b) Other long-term liabilities	3.44	-
	118.60	98.29
Current liabilities		
(a) Short-term borrowings	1,888.54	1,853.43
(b) Trade payables		
Total outstanding dues of micro enterprises and small enterprises; and	424.46	70.06
Total outstanding dues of creditors other than micro enterprises and small enterprises	184.91	118.40
(c) Other current liabilities	286.91	204.32
(d) Short-term provisions	137.24	142.09
	2,922.06	2,388.30
	8,849.71	7,941.66
ASSETS		
1 Non-current assets		
(a) Property, Plant and Equipment and Intangible assets		
i. Property, Plant and Equipments	24.15	16.94
ii. Intangible assets	52.65	12.06
iii. Intangible assets under development	24.29	39.74
(b) Deferred tax assets (Net)	53.83	46.97
(c) Long term loans and advances	55.45	31.21
(d) Other non-current assets	126.35	133.53
	336.73	280.45
2 Current assets		
(a) Inventories	2,594.15	1,975.04
(b) Trade receivables	5,420.56	3,722.52
(c) Cash and bank balance	105.78	1,624.33
(d) Short term loans and advances	3.36	3.34
(e) Other current assets	389.13	335.98
	8,512.98	7,661.21
	8,849.71	7,941.66

See accompanying Notes to Financial Results

For and on behalf of
Aakaar Medical Technologies Limited*D. Meswani*Dilip Meswani
Managing Director
DIN 06540985

Place: Mumbai

Date: October 30, 2026



AAKAAR MEDICAL TECHNOLOGIES LIMITED

(Formerly known as AAKAAR MEDICAL TECHNOLOGIES PRIVATE LIMITED)

Registered Address: A-801, Heritage Plaza, Teli Gali, Cross Road, Andheri (E), Mumbai 400069

CIN : L74900MH2013PLC244717

Statement of Cash Flows for the half year ended September 30, 2026

Particulars	(Amount in Lacs)	
	For the half year ended September 30, 2026 (Unaudited)	For the year ended March 31, 2026 (Audited)
A. Cash flow from operating activities		
Net Profit / (Loss) before tax	481.96	919.18
Adjustments for:		
Depreciation and amortisation	6.81	12.83
Interest income	(18.95)	(77.97)
Balance written back	(7.77)	(0.01)
Sundry balances written off	1.06	30.43
Foreign exchange gain/ loss	10.08	(1.51)
Finance costs	70.52	165.45
Assets written off	2.64	-
Operating profit / (loss) before changes in operating assets	546.35	1,048.40
Changes in Operating Assets:		
Adjustments for (increase) / decrease in operating assets:		
(Increase)/ Decreases in trade receivables	(1,699.10)	(952.50)
(Increase)/ Decreases in inventories	(619.11)	(519.61)
(Increase)/ Decreases in other assets	(53.05)	13.07
(Increase)/ Decreases in loans and advances	1.67	7.39
Increase/ (Decrease) in trade payables	418.60	(161.18)
Increase/ (Decrease) in provisions	41.68	33.10
Increase/ (Decrease) in other current liabilities	82.59	(79.78)
Cash generated from operations	(1,280.37)	(611.11)
Net income tax (paid) / refunds received	(186.89)	(225.01)
Net cash flow used in operating activities	(1,467.26)	(836.12)
B. Cash flow from investing activities		
Purchase of fixed asset	(41.80)	(57.82)
Interest received	40.01	57.76
Term deposits	7.18	4.93
Net cash flow used in investing activities	5.39	4.87
C. Cash flow from financing activities		
Proceeds from cash credit/ overdraft facility	35.11	(165.79)
Net Increase / (Decrease) of borrowings	-	(254.60)
Proceeds from issue of shares	-	2,700.29
Share issue expenses	(0.10)	(234.81)
Finance cost	(70.52)	(165.45)
Net cash flow generated from financing activities	(35.51)	1,879.64
Net increase/(decrease) in Cash and cash equivalents (A+B+C)	(1,497.38)	1,048.38
Cash and cash equivalents at the beginning of the year	1,603.03	554.64
Cash and cash equivalents at the end of the year	105.65	1,603.03
Components of cash and cash equivalents		
Balance with banks and cash on hand	105.65	1,603.03
	105.65	1,603.03

The Cash Flow Statement has been Prepared under the "Indirect Method" as set out in Accounting Standard 3 on Cash Flow Statements issued by the Institute of Chartered Accountants of India.
See accompanying Notes to Financial Results



For and on behalf of
Aakaar Medical Technologies Limited

D. Meswani

Dilip Meswani
Managing Director
DIN 06540985

Place: Mumbai
Date: October 30, 2026

Notes to Unaudited Financial Results for Half Year Ended September 30, 2026

1. The Financial Results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognized accounting practices and policies as applicable.
2. The above results for the half year ended September 30, 2026 were reviewed by Audit Committee and were approved and taken on record by the Board of Directors in their meeting held on October 30, 2026.
3. Basic and Diluted EPS for the half year ended September 30, 2026 is calculated on the basis of 1,41,72,816 equity shares.
4. The Company operates through two segments viz. manufacturing and distribution of medical equipment and cosmetic medicines. Details of the same are as per the annexure attached.
5. The details of utilization of IPO Proceeds of Rs. 2700.29 lakhs are as follows:

(Rs. in lacs)

Particulars	Proceeds	Utilisation upto 30 th September, 2026	Unutilised upto 30 th September, 2026
Working Capital	2,035.00	2035.00	-
General Corporate Purpose*	329.00	329.00	-
Issue expenses paid with GST	336.29	336.29	-
Total	2,700.29	2700.29	-

(*The GCP Component 329.00 includes issues expenses 0.74 Lacs with GST on and above estimated issue expenses of Rs. 336.29 lacs paid - with GST.)

6. Previous year figures have been regrouped / rearranged wherever necessary to correspond with the current year's classification / disclosures.

For Aakaar Medical Technologies Limited



Dilip Meswani
Founder & Managing Director
DIN - 06540985
Place: Mumbai
Dated: October 30, 2026



Annexure

S.No.	Particulars	For the half year ended		For the year ended
		30th Sep, 2026 (Unaudited)	30th Sep, 2025 (Unaudited)	31st Mar, 2026 (Audited)
A	Segment Revenue			
	Aesthetic Devices & Device consumables	344.99	335	735.66
	Aesthetic Products	4027.35	2197.49	5960.75
	Total Revenue	4372.34	2532.49	6696.41
B	Result			
	Segment Profit/loss			
	Aesthetic Devices & Device consumables	367.52	167.5	435.82
	Aesthetic Products	1757.51	976.96	2384.69
	Segment Operating Profit	2247.31	1388.03	3875.90
	Reconciliation of segment operating profit to operating profit			
	Unallocated:			
	Employee Benefit Expense	807.02	726.4	1401.08
	Other Expense	904.27	689.6	1456.47
	Other miscellaneous expenses net of income	(26.80)	(29.71)	(80.44)
	Operating Profit	562.82	1.74	1,098.79
	Finance Costs	(80.85)	(104.07)	(179.61)
	Profit before tax	481.96	(102.33)	919.18
C	Segment Assets			
	Aesthetic Devices & Device consumables	1379.26	122.68	1035.23
	Aesthetic Products	6635.45	2526.72	4662.33
	Unallocated Corporate Assets	835.00	4467.03	2244.11
	Total Assets	8849.71	7116.43	7941.67
D	Segment Liabilities			
	Unallocated Corporate liabilities	3040.66	2402.51	2486.6
	Total Liabilities	3040.66	2402.51	2486.6

D. R. M. M.



October 30, 2026

To,
The Board of Directors,
Aakaar Medical Technologies Limited
A-801, Heritage Plaza, Teli Gali Cross Road,
Andheri (East), Mumbai - 400069

Re: **Certificate under Regulation 33 (2)(a) of SEBI (LODR) Regulations, 2015**


Dear Sir,

We, the undersigned, being the Chief Executive Officer & Director and the Chief Financial Officer of Aakaar Medical Technologies Ltd. (the "Company"), hereby certify for the half year ended 30th September, 2026: -

1. That the Company has complied with all the applicable requirements of the Regulation 33 (2) (a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which inter alia requires that the Company file its Standalone Financial Results for the relevant period with the Stock Exchange(s), along with the limited review or audit thereof, and such results have been forwarded to the stock exchange(s) where the Company's securities are listed.
2. That to the best of our knowledge and belief, the financial statements of the Company prepared for the said period give a true and fair view of the affairs of the Company, and have been prepared in accordance with the applicable accounting standards and other statutory requirements.
3. That we certify that the financial results do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading in the Company's financial results as filed with the stock exchange.
4. That we further confirm that the Company has made disclosures to the stock exchange(s) under the SEBI LODR Regulations as required, and there are no instances of non-compliance with the said Regulations which, in our view, would materially effect the ability of the Company to continue as a going concern or to fulfil its obligations to the stock exchange(s) or shareholders.

We request you to kindly take this certificate on record.

For and on behalf of
Aakaar Medical Technologies Ltd.


Dr. Rahul Babasaheb Sawakhande
Chief Executive Officer & Director





Rakesh Parekh
Chief Financial Officer

Independent Auditor's Review Report on Unaudited Standalone Half Yearly Financial Results of Aakaar Medical Technologies Limited in pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Members of Aakaar Medical Technologies Limited
(formerly known as Aakaar Medical Technologies Private Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Aakaar Medical Technologies Limited ("The Company") for the half year ended September 30, 2026 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The preparation of the statement, which is the responsibility of the Company's Management and approved by the Board of Directors, in accordance with the recognition and measurement principles laid down in Accounting Standard 25, (AS 25) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). Our responsibility is to issue a report on these statements based on our review.
3. We conducted our review of the statements in accordance with Standards on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



CHARTERED ACCOUNTANTS

4. Based on our review conducted above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards (AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For C.B. Mehta and Associates

Chartered Accountants

FRN 124978W



C.B. Mehta

Proprietor

MRN: 116543

Place: Mumbai

Date: October 30, 2026

UDIN: 26116543 VEHG MG 8738

